Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL5690575 | 1.00 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL2320943 | 1.00 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL2189391 | 1.00 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL17927669 | 1.00 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL726113 | 1.00 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL16053680 | 1.00 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL2910615 | 1.00 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL28113587 | 1.00 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL3917721 | 1.00 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL17513007 | 0.95 | SLC34A1 (0.54) | SLC34A1LMNAKDM4ECYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731002-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12611435-B2 | Microencapsulation of bacteriophages and related products | Precisio Biotix Therapeutics, Inc. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260109940-A1 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | TENFOLD TECH LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12365868-B2 | Systems for production of products to promote nitrogen use efficiency in plants | Tenfold Technologies, LLC (US) | 2025-07-22 | — | — | US | disclosed |
| US-12365869-B2 | Systems for production of products to promote nitrogen use efficiency in plants | Tenfold Technologies, LLC (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240425789-A1 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC | 2024-12-26 | — | — | US | disclosed |
| US-20240425804-A1 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC | 2024-12-26 | — | — | US | disclosed |
| WO-2024263793-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024241248-A1 | COMPOUNDS TARGETING KRAS G12D MUTATIONS AND THEIR USES | INNOPHARMASCREEN INC. (KR) | 2024-11-28 | — | — | WO | disclosed |
| US-11745026-B2 | Laser assisted wound healing protocol and system | THE BIOREGENTECH INSTITUTE, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230211173-A1 | LASER ASSISTED WOUND HEALING PROTOCOL AND SYSTEM | THE BIOREGENTECH INSTITUTE, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11684797-B2 | Laser assisted wound healing protocol and system | THE BIOREGENTECH INSTITUTE, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11654293-B2 | Laser assisted wound healing protocol and system | THE BIOREGENTECH INSTITUTE, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20220409683-A1 | MICROENCAPSULATION OF BACTERIOPHAGES AND RELATED PRODUCTS | Precisio Biotix Therapeutics, Inc. | 2022-12-29 | — | — | US | disclosed |
| US-20220257970-A1 | LASER ASSISTED WOUND HEALING PROTOCOL AND SYSTEM | THE BIOREGENTECH INSTITUTE, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11413319-B2 | Microencapsulation of bacteriophages and related products | PHAGELUX (CANADA) INC. (CA) | 2022-08-16 | — | — | US | disclosed |
| US-11389663-B2 | Laser assisted wound healing protocol and system | BIOREGENTECH, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-1999053777-A1 | NUTRITIONAL SUPPLEMENT FOR PREGNANT AND LACTATING WOMEN | NOVARTIS NUTRITION AG (CH) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109940-A1 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | MASTL, PURB, MRPL21 | SLC34A1 153/4885LMNA 1283/4885KDM4E 2907/4885 |
| US-11413319-B2 | Microencapsulation of bacteriophages and related products | POLI, POLM, CLPP | SLC34A1 3697/4885LMNA 294/4885KDM4E 3672/4885 |
| US-12611435-B2 | Microencapsulation of bacteriophages and related products | POLI, POLM, POLL | SLC34A1 2201/4885LMNA 854/4885KDM4E 2965/4885 |
| US-20220409683-A1 | MICROENCAPSULATION OF BACTERIOPHAGES AND RELATED PRODUCTS | POLI, POLM, CLPP | SLC34A1 3697/4885LMNA 294/4885KDM4E 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.